{"id":47613,"date":"2022-08-24T14:02:11","date_gmt":"2022-08-24T12:02:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/"},"modified":"2022-08-24T14:02:11","modified_gmt":"2022-08-24T12:02:11","slug":"ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/","title":{"rendered":"Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1\/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP\u2122 Protein Degrader"},"content":{"rendered":"
\n

\nStudy will evaluate the first protein degrader developed using Ranok\u2019s innovative CHAMP\u2122 <\/i>technology in patients with advanced solid tumors or diffuse large B-cell lymphoma (DLBCL)<\/i>\n<\/p>\n

<\/a><\/p>\n

BOSTON & HANGZHOU, China–(BUSINESS WIRE)–Ranok Therapeutics<\/a>, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancer and other serious diseases, today announced the initiation of patient dosing in the U.S. for a Phase 1\/2 study of RNK05047. The trial, entitled CHAMP-1, will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RNK05047 in patients with advanced solid tumors or diffuse large B-cell lymphoma (<\/i>DLBCL). Ranok anticipates preliminary data from the study in the second half of 2023.\n<\/p>\n

\n\u201cRNK05047 is Ranok\u2019s first therapy based on our proprietary CHAMP\u2122 technology, as well as the first BRD4 protein degrader in the pharmaceutical industry to enter clinical testing,\u201d said Weiwen Ying, Ph.D., Founder and Chief Executive Officer of Ranok. \u201cRNK05047 is designed to selectively degrade BRD4 protein preferentially in tumors, thereby improving safety and efficacy, which differentiates it from other investigational therapies such as non-selective BET inhibitors.\u201d\n<\/p>\n

\n\u201cThe BET bromodomain transcription factor BRD4 is a master regulator of oncogenes involved in diverse cancer types,\u201d said Manuel Hidalgo Medina, M.D., Ph.D., Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and New York-Presbyterian\/Weill Cornell Medical Center, Associate Director of Clinical Services at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and a site Principal Investigator in the trial. \u201cWe are pleased to be participating in this trial and are hopeful that RNK05047 will provide a beneficial new therapeutic option for patients.\u201d\n<\/p>\n

\nAdditional information on this clinical trial (NCT05487170) can be found at www.clinicaltrials.gov<\/a>.\n<\/p>\n

\nAbout Ranok\u2019s CHAMP\u2122 platform<\/b>\n<\/p>\n

\nRanok\u2019s proprietary Chaperone-mediated Protein Degradation\/Degrader (CHAMP\u2122) platform and Chaperone-Tether Library\u2122 are based on our founders\u2019 extensive backgrounds researching protein homeostasis. CHAMP\u2122 technology takes advantage of the cellular chaperone network, which regulates the folding and stability of proteins, distinguishing it from other targeted protein degradation approaches. CHAMP\u2122 has a number of unique advantages, such as the evasion of mechanisms of drug resistance, and is designed to improved safety and efficacy due to the selective targeting of disease tissues.\n<\/p>\n

\nAbout RNK05047<\/b>\n<\/p>\n

\nRNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok\u2019s proprietary approach to targeted protein degradation, CHAMP\u2122. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC<\/i> and BCL2<\/i> and is involved in diverse cancer types. CHAMP-1 is a Phase 1\/2 trial of RNK05047 currently underway in the U.S. that will assess its safety, tolerability and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamic readouts as secondary endpoints. Preliminary data is expected from the trial in the second half of 2023.\n<\/p>\n

\nAbout Ranok Therapeutics<\/b>\n<\/p>\n

\nRanok is a privately held biopharmaceutical company that is pioneering CHAMP\u2122, an innovative approach to targeted protein degradation for the discovery and development of novel therapeutics. Our R&D team brings deep biological insight and chemistry expertise to rapidly identify and advance CHAMP\u2122 degraders for a variety of important disease targets, with the goal to create transformative medicines that benefit patients around the world suffering from cancer and other serious diseases. For more information, please visit the company website at www.ranoktherapeutics.com<\/a> or follow us on Twitter (@RanokTx<\/a>) and LinkedIn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nUS Media & Investor:
\n
<\/b>Ms. Beth Kurth
\n
Conway Communications
\n
bkurth@conwaycommsir.com<\/a>\n<\/p>\n

\nChina Media & Investor:
\n
<\/b>Mr. Lei Zhang
\n
Ranok Therapeutics
\n
bd@ranoktherapeutics.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Study will evaluate the first protein degrader developed using Ranok\u2019s innovative CHAMP\u2122 technology in patients with advanced solid tumors or diffuse large B-cell lymphoma (DLBCL) BOSTON & HANGZHOU, China–(BUSINESS WIRE)–Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancer and other serious diseases, today … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47613","6":"format-standard","7":"category-industry"},"yoast_head":"\nRanok Therapeutics Announces Initiation of Patient Dosing in a Phase 1\/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP\u2122 Protein Degrader - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1\/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP\u2122 Protein Degrader - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Study will evaluate the first protein degrader developed using Ranok\u2019s innovative CHAMP\u2122 technology in patients with advanced solid tumors or diffuse large B-cell lymphoma (DLBCL) BOSTON & HANGZHOU, China–(BUSINESS WIRE)–Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancer and other serious diseases, today ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-24T12:02:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220823005879\/en\/1552137\/21\/Ranok_Tx_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1\\\/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP\u2122 Protein Degrader\",\"datePublished\":\"2022-08-24T12:02:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\\\/\"},\"wordCount\":609,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220823005879\\\/en\\\/1552137\\\/21\\\/Ranok_Tx_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\\\/\",\"name\":\"Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1\\\/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP\u2122 Protein Degrader - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220823005879\\\/en\\\/1552137\\\/21\\\/Ranok_Tx_Logo.jpg\",\"datePublished\":\"2022-08-24T12:02:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220823005879\\\/en\\\/1552137\\\/21\\\/Ranok_Tx_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220823005879\\\/en\\\/1552137\\\/21\\\/Ranok_Tx_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1\\\/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP\u2122 Protein Degrader\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1\/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP\u2122 Protein Degrader - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/","og_locale":"en_US","og_type":"article","og_title":"Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1\/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP\u2122 Protein Degrader - Pharma Trend","og_description":"Study will evaluate the first protein degrader developed using Ranok\u2019s innovative CHAMP\u2122 technology in patients with advanced solid tumors or diffuse large B-cell lymphoma (DLBCL) BOSTON & HANGZHOU, China–(BUSINESS WIRE)–Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancer and other serious diseases, today ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-24T12:02:11+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220823005879\/en\/1552137\/21\/Ranok_Tx_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1\/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP\u2122 Protein Degrader","datePublished":"2022-08-24T12:02:11+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/"},"wordCount":609,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220823005879\/en\/1552137\/21\/Ranok_Tx_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/","url":"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/","name":"Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1\/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP\u2122 Protein Degrader - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220823005879\/en\/1552137\/21\/Ranok_Tx_Logo.jpg","datePublished":"2022-08-24T12:02:11+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220823005879\/en\/1552137\/21\/Ranok_Tx_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220823005879\/en\/1552137\/21\/Ranok_Tx_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ranok-therapeutics-announces-initiation-of-patient-dosing-in-a-phase-1-2-clinical-trial-of-rnk05047-a-first-in-class-brd4-targeting-champ-protein-degrader\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1\/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP\u2122 Protein Degrader"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47613"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47613\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}